<!DOCTYPE html><html><head><meta charset="utf-8"></meta><meta name="viewport" content="width=device-width" initial-scale="1"></meta><style>
      /* Create a running element */
      #header-and-footer {
        position: running(header-and-footer);
        text-align: right;
      }

      /* Add that running element to the top and bottom of every page */
      @page {
        @top {
          content: element(header-and-footer);
        }
        @bottom {
          content: element(header-and-footer);
        }
      }

      /* Add a page number */
      #page-number {
        content: "Page " counter(page);
      }

      @page { size: A4 }

      /* Create a title page with a full-bleed background and no header */
      /* Create a soa page with landscape orientation */
      #title-page {
        page: title-page;
      }
      .soa-page {
        page: soa-page
      }

      @page title-page {
        @top {
          content: "";
        }
      }

      @page soa-page {
        size: A4 landscape
      }

      #title-page h1 {
        padding: 200px 0 40px 0;
        font-size: 30px;
      }

      /* Dynamically create a table of contents with leaders */
      #table-of-contents a {
        content: target-content(attr(href)) leader('.') target-counter(attr(href), page);
        color: #000000;
        text-decoration: none;
        display: block;
        padding-top: 5px;
      }

      /* Float the footnote to a footnotes area on the page */
      .footnote {
        float: footnote;
        font-size: small;
      }

      .page {
        page-break-after: always;
      }

      body {
        counter-reset: chapter;
        font-family: 'Times New Roman';
        color: #000000;
      }

      .usdm-warning {
        font-style: italic;
        color: red;
      }

      .soa-body-text {
        font-size: 10px;
        text-align: center
      }

      .soa-activity-text {
        font-size: 10px;
        text-align: left
      }

      .soa-footnote-text {
        font-size: 12px;
        text-align: left
      }

      .usdm-highlight {
        background-color: LightGray !important;
      }

      .usdm-highlight p {
        background-color: LightGray;
      }

      p .usdm-highlight {
        background-color: LightGray;
      }

      .usdm-highlight-link {
        text-decoration:none;
      }

    </style><link href="https://fonts.googleapis.com/css2?family=Open+Sans:wght@400;600;800&amp;display=swap" rel="stylesheet"></link><link href="https://cdn.jsdelivr.net/npm/bootstrap-icons@1.9.1/font/bootstrap-icons.css" rel="stylesheet" type="text/css"></link><link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.2/dist/css/bootstrap.min.css" rel="stylesheet" integrity="sha384-T3c6CoIi6uLrA9TneNEoa7RxnatzjcDSCmG1MXxSR1GAsXEV/Dwwykc2MPK8M2HN" crossorigin="anonymous"></link><script src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.2/dist/js/bootstrap.bundle.min.js" integrity="sha384-C6RzsynM9kWDrMNeT87bh95OGNyZPhcTNXj1NW7RuBCsyN/o0jlpcV8Qyq46cDfL" crossorigin="anonymous"></script></head><body>
      <div id="title-page" class="page">
        <div class="container">
          <div class="row">
            <div class="col-md-8 offset-md-2 text-center">
              <h1>Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease</h1>
            </div>
          </div>
          <div class="row mt-5">
            <div class="col-md-8 offset-md-2 text-center">
              <p class="usdm-warning">Note:</p>
              <p class="usdm-warning">This document is generated from content held within the Unified Studies Definitions Model. It is for test purposes only.</p>
            </div>
          </div>
        </div>
        <div id="header-and-footer">
          <span id="page-number"></span>
        </div>
      </div>
    <div class="page"><div xmlns="http://www.w3.org/1999/xhtml"><table><tr><th style="vertical-align: top; text-align: left"><p>Sponsor Confidentiality Statement:</p></th><td style="vertical-align: top; text-align: left"><p></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Full Title:</p></th><td style="vertical-align: top; text-align: left"><p>Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Trial Acronym:</p></th><td style="vertical-align: top; text-align: left"><p>LZZT</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Protocol Identifier:</p></th><td style="vertical-align: top; text-align: left"><p>H2Q-MC-LZZT</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Original Protocol:</p></th><td style="vertical-align: top; text-align: left"><p></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Version Number:</p></th><td style="vertical-align: top; text-align: left"><p>2</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Version Date:</p></th><td style="vertical-align: top; text-align: left"><p>2006-06-01</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Amendment Identifier:</p></th><td style="vertical-align: top; text-align: left"><p>1</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Amendment Scope:</p></th><td style="vertical-align: top; text-align: left"><p>Global</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Compound Codes(s):</p></th><td style="vertical-align: top; text-align: left"><p></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Compound Name(s):</p></th><td style="vertical-align: top; text-align: left"><p></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Trial Phase:</p></th><td style="vertical-align: top; text-align: left"><p>Phase II Trial</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Short Title:</p></th><td style="vertical-align: top; text-align: left"><p>Xanomeline (LY246708)</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Sponsor Name and Address:</p></th><td style="vertical-align: top; text-align: left"><p>Eli Lilly, Lilly Corporate Ctr, Indianapolis, , IN, 4628, United States of America</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Regulatory Agency Identifier Number(s):</p></th><td style="vertical-align: top; text-align: left"><p>NCT12345678</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Spondor Approval Date:</p></th><td style="vertical-align: top; text-align: left"><p>2006-07-01</p></td></tr></table></div></div><div class="page">
      <div id="toc-page" class="page">
        <div id="table-of-contents">
          <a href="#section-1"></a><a href="#section-2"></a><a href="#section-3"></a><a href="#section-4"></a><a href="#section-5"></a><a href="#section-6"></a><a href="#section-7"></a><a href="#section-8"></a><a href="#section-9"></a><a href="#section-10"></a><a href="#section-11"></a><a href="#section-12"></a><a href="#section-13"></a><a href="#section-14"></a>
        </div>
        <div align="center">
          <br/>
          <p class="usdm-warning">Note:</p>
          <p class="usdm-warning">The table of contents is auto generated upon PDF production and only includes first level sections.</p>
        </div>
        <div id="header-and-footer">
          <span id="page-number"></span>
        </div>
      </div>
    </div><div class="page"><h1 id="section-1">1 PROTOCOL SUMMARY</h1></div><div class=""><h2 id="section-1.1">1.1 Protocol Synopsis</h2></div><div class=""><h3 id="section-1.1.1">1.1.1 Primary and Secondary Objectives and Estimands</h3></div><div class=""><h3 id="section-1.1.2">1.1.2 Overall Design</h3></div><div class=""><h2 id="section-1.2">1.2 Trial Schema</h2></div><div class=""><h2 id="section-1.3">1.3 Schedule of Activities</h2></div><div class="page"><h1 id="section-2">2 INTRODUCTION</h1></div><div class=""><h2 id="section-2.1">2.1 Purpose of Trial</h2></div><div class=""><h2 id="section-2.2">2.2 Summary of Benefits and Risks</h2></div><div class=""><h3 id="section-2.2.1">2.2.1 Benefit Summary</h3></div><div class=""><h3 id="section-2.2.2">2.2.2 Risk Summary and Mitigation Strategy</h3></div><div class=""><h3 id="section-2.2.3">2.2.3 Overall Benefit:Risk Conclusion</h3></div><div class="page"><h1 id="section-3">3 TRIAL OBJECTIVES AND ESTIMANDS</h1></div><div class=""><h2 id="section-3.1">3.1 Primary Objective(s) and Associated Estimand(s)</h2><div xmlns="http://www.w3.org/1999/xhtml"><p>The primary objectives of this study are</p>
<ul>
<li>To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).</li>
<li>To document the safety profile of the xanomeline TTS.</li>
</ul></div></div><div class=""><h3 id="section-3.1.1">3.1.1 {Primary Estimand}</h3></div><div class=""><h2 id="section-3.2">3.2 Secondary Objective(s) and Associated Estimand(s)</h2><div xmlns="http://www.w3.org/1999/xhtml"><p>The secondary objectives of this study are</p>
<ul>
<li>To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.</li>
<li>To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).</li>
<li>To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).</li>
<li>To assess the treatment response as a function of Apo E genotype.</li>
</ul></div></div><div class=""><h2 id="section-3.3">3.3 Exploratory Objective(s)</h2></div><div class="page"><h1 id="section-4">4 TRIAL DESIGN</h1></div><div class=""><h2 id="section-4.1">4.1 Description of Trial Design</h2></div><div class=""><h3 id="section-4.1.1">4.1.1 Stakeholder Input into Design</h3></div><div class=""><h2 id="section-4.2">4.2 Rationale for Trial Design</h2></div><div class=""><h3 id="section-4.2.1">4.2.1 Rationale for Intervention Model</h3></div><div class=""><h3 id="section-4.2.2">4.2.2 Rationale for Duration</h3></div><div class=""><h3 id="section-4.2.3">4.2.3 Rationale for Estimands</h3></div><div class=""><h3 id="section-4.2.4">4.2.4 Rationale for Interim Analysis</h3></div><div class=""><h3 id="section-4.2.5">4.2.5 Rationale for Control Type</h3></div><div class=""><h3 id="section-4.2.6">4.2.6 Rationale for Adaptive or Novel Trial Design</h3></div><div class=""><h3 id="section-4.2.7">4.2.7 Rationale for Other Trial Design Aspects</h3></div><div class=""><h2 id="section-4.3">4.3 Trial Stopping Rules</h2></div><div class=""><h2 id="section-4.4">4.4 Start of Trial and End of Trial</h2></div><div class=""><h2 id="section-4.5">4.5 Access to Trial Intervention After End of Trial</h2></div><div class="page"><h1 id="section-5">5 TRIAL POPULATION</h1></div><div class=""><h2 id="section-5.1">5.1 Description of Trial Population and Rationale</h2></div><div class=""><h2 id="section-5.2">5.2 Inclusion Criteria</h2></div><div class=""><h2 id="section-5.3">5.3 Exclusion Criteria</h2></div><div class=""><h2 id="section-5.4">5.4 Contraception</h2></div><div class=""><h3 id="section-5.4.1">5.4.1 Definitions Related to Childbearing Potential</h3></div><div class=""><h3 id="section-5.4.2">5.4.2 Contraception Requirements</h3></div><div class=""><h2 id="section-5.5">5.5 Lifestyle Restrictions</h2></div><div class=""><h3 id="section-5.5.1">5.5.1 Meals and Dietary Restrictions</h3></div><div class=""><h3 id="section-5.5.2">5.5.2 Caffeine, Alcohol, Tobacco,and Other Restrictions</h3></div><div class=""><h3 id="section-5.5.3">5.5.3 Physical Activity Restrictions</h3></div><div class=""><h3 id="section-5.5.4">5.5.4 Other Activity Restrictions</h3></div><div class=""><h2 id="section-5.6">5.6 Screen Failure and Rescreening</h2></div><div class="page"><h1 id="section-6">6 TRIAL INTERVENTION AND CONCOMITANT THERAPY</h1></div><div class=""><h2 id="section-6.1">6.1 Overview of Trial Interventions</h2></div><div class=""><h2 id="section-6.2">6.2 Description of Investigational Trial Intervention</h2></div><div class=""><h2 id="section-6.3">6.3 Rationale for Investigational Trial Intervention Dose and Regimen</h2></div><div class=""><h2 id="section-6.4">6.4 Investigational Trial Intervention Administration</h2></div><div class=""><h2 id="section-6.5">6.5 Investigational Trial Intervention Dose Modification</h2></div><div class=""><h2 id="section-6.6">6.6 Management of Investigational Trial Intervention Overdose</h2></div><div class=""><h2 id="section-6.7">6.7 Preparation,Storage,Handling and Accountability of Investigational Trial Intervention(s)</h2></div><div class=""><h3 id="section-6.7.1">6.7.1 Preparation of Investigational Trial Intervention(s)</h3></div><div class=""><h3 id="section-6.7.2">6.7.2 Storage and Handling of Investigational Trial Intervention</h3></div><div class=""><h3 id="section-6.7.3">6.7.3 Accountability of Investigational Trial Intervention</h3></div><div class=""><h2 id="section-6.8">6.8 Investigational Trial Intervention Assignment,Randomisation and Blinding</h2></div><div class=""><h3 id="section-6.8.1">6.8.1 Participant Assignment to Investigational Trial Intervention</h3></div><div class=""><h3 id="section-6.8.2">6.8.2 Randomisation</h3></div><div class=""><h3 id="section-6.8.3">6.8.3 {Blinding}</h3></div><div class=""><h3 id="section-6.8.4">6.8.4 {Emergency Unblinding at the Site}</h3></div><div class=""><h2 id="section-6.9">6.9 Investigational Trial Intervention Compliance</h2></div><div class=""><h2 id="section-6.10">6.10 Description of Non-Investigational Trial Intervention(s)</h2></div><div class=""><h3 id="section-6.10.1">6.10.1 {Background Intervention}</h3></div><div class=""><h3 id="section-6.10.2">6.10.2 {Rescue Therapy}</h3></div><div class=""><h3 id="section-6.10.3">6.10.3 {Other Non-investigational Intervention}</h3></div><div class=""><h2 id="section-6.11">6.11 Concomitant Therapy</h2></div><div class=""><h3 id="section-6.11.1">6.11.1 {Prohibited Concomitant Therapy}</h3></div><div class=""><h3 id="section-6.11.2">6.11.2 {Permitted Concomitant Therapy}</h3></div><div class="page"><h1 id="section-7">7 PARTICIPANT DISCONTINUATION OF TRIAL INTERVENTION AND DISCONTINUATION OR WITHDRAWAL FROM TRIAL</h1></div><div class=""><h2 id="section-7.1">7.1 Discontinuation of Trial Intervention for Individual Participants</h2></div><div class=""><h3 id="section-7.1.1">7.1.1 Permanent Discontinuation of Trial Intervention</h3></div><div class=""><h3 id="section-7.1.2">7.1.2 Temporary Discontinuation of Trial Intervention</h3></div><div class=""><h3 id="section-7.1.3">7.1.3 Rechallenge</h3></div><div class=""><h2 id="section-7.2">7.2 Discontinuation or Withdrawal from the Trial</h2></div><div class=""><h2 id="section-7.3">7.3 Lost to Follow-Up</h2></div><div class="page"><h1 id="section-8">8 TRIAL ASSESSMENTS AND PROCEDURES</h1></div><div class=""><h2 id="section-8.1">8.1 Trial Assessments and Procedures Considerations</h2></div><div class=""><h2 id="section-8.2">8.2 Screening/Baseline Assessments and Procedures</h2></div><div class=""><h2 id="section-8.3">8.3 Efficacy Assessments and Procedures</h2></div><div class=""><h2 id="section-8.4">8.4 Safety Assessments and Procedures</h2></div><div class=""><h3 id="section-8.4.1">8.4.1 {Physical Examination}</h3></div><div class=""><h3 id="section-8.4.2">8.4.2 {Vital Signs}</h3></div><div class=""><h3 id="section-8.4.3">8.4.3 {Electrocardiograms}</h3></div><div class=""><h3 id="section-8.4.4">8.4.4 {Clinical Laboratory Assessments}</h3></div><div class=""><h3 id="section-8.4.5">8.4.5 {Pregnancy Testing}</h3></div><div class=""><h3 id="section-8.4.6">8.4.6 {Suicidal Ideation and Behaviour Risk Monitoring}</h3></div><div class=""><h2 id="section-8.5">8.5 Pharmacokinetics</h2></div><div class=""><h2 id="section-8.6">8.6 Biomarkers</h2></div><div class=""><h3 id="section-8.6.1">8.6.1 Genetics and Pharmacogenomics</h3></div><div class=""><h3 id="section-8.6.2">8.6.2 Pharmacodynamic Biomarkers</h3></div><div class=""><h3 id="section-8.6.3">8.6.3 {Other Biomarkers}</h3></div><div class=""><h2 id="section-8.7">8.7 Immunogenicity Assessments</h2></div><div class=""><h2 id="section-8.8">8.8 Medical Resource Utilisation and Health Economics</h2></div><div class="page"><h1 id="section-9">9 ADVERSE EVENTS,SERIOUS ADVERSE EVENTS,PRODUCT COMPLAINTS,PREGNANCY AND POSTPARTUM INFORMATION</h1></div><div class=""><h2 id="section-9.1">9.1 Definitions</h2></div><div class=""><h3 id="section-9.1.1">9.1.1 Definitions of Adverse Events</h3></div><div class=""><h3 id="section-9.1.2">9.1.2 Definitions of Serious Adverse Events</h3></div><div class=""><h3 id="section-9.1.3">9.1.3 {Definition of Medical Device Product Complaints}</h3></div><div class=""><h2 id="section-9.2">9.2 Timing and Mechanism for Collection and Reporting</h2></div><div class=""><h2 id="section-9.3">9.3 Identification,Recording and Follow-Up</h2></div><div class=""><h3 id="section-9.3.1">9.3.1 Identification</h3></div><div class=""><h3 id="section-9.3.2">9.3.2 Severity</h3></div><div class=""><h3 id="section-9.3.3">9.3.3 Causality</h3></div><div class=""><h3 id="section-9.3.4">9.3.4 Follow-up</h3></div><div class=""><h2 id="section-9.4">9.4 Reporting</h2></div><div class=""><h3 id="section-9.4.1">9.4.1 Regulatory Reporting Requirements</h3></div><div class=""><h3 id="section-9.4.2">9.4.2 Adverse Events of Special Interest</h3></div><div class=""><h3 id="section-9.4.3">9.4.3 Disease-related Events or Outcomes Not Qualifying as AEs or SAEs</h3></div><div class=""><h2 id="section-9.5">9.5 Pregnancy and Postpartum Information</h2></div><div class=""><h3 id="section-9.5.1">9.5.1 {Participants Who Become Pregnant During the Trial}</h3></div><div class=""><h3 id="section-9.5.2">9.5.2 {Participants Whose Partners Become Pregnant}</h3></div><div class="page"><h1 id="section-10">10 STATISTICAL CONSIDERATIONS</h1></div><div class=""><h2 id="section-10.1">10.1 General Considerations</h2></div><div class=""><h2 id="section-10.2">10.2 Analysis Sets</h2></div><div class=""><h2 id="section-10.3">10.3 Analyses of Demographics and Other Baseline Variables</h2></div><div class=""><h2 id="section-10.4">10.4 Analyses Associated with the Primary Objective(s)</h2></div><div class=""><h3 id="section-10.4.1">10.4.1 Statistical Method of Analysis</h3></div><div class=""><h3 id="section-10.4.2">10.4.2 Handling of Data in Relation to Primary Estimand(s)</h3></div><div class=""><h3 id="section-10.4.3">10.4.3 Handling of Missing Data</h3></div><div class=""><h3 id="section-10.4.4">10.4.4 {Sensitivity Analysis}</h3></div><div class=""><h3 id="section-10.4.5">10.4.5 {Supplementary Analysis}</h3></div><div class=""><h2 id="section-10.5">10.5 Analysis Associated with the Secondary Objective(s)</h2></div><div class=""><h3 id="section-10.5.1">10.5.1 {Statistical Method of Analysis}</h3></div><div class=""><h3 id="section-10.5.2">10.5.2 {Handling of Data in Relation to Secondary Estimand(s)}</h3></div><div class=""><h3 id="section-10.5.3">10.5.3 {Handling of Missing Data}</h3></div><div class=""><h3 id="section-10.5.4">10.5.4 {Sensitivity Analyses}</h3></div><div class=""><h3 id="section-10.5.5">10.5.5 {Supplementary Analyses}</h3></div><div class=""><h2 id="section-10.6">10.6 Analysis Associated with the Exploratory Objective(s)</h2></div><div class=""><h2 id="section-10.7">10.7 Safety Analyses</h2></div><div class=""><h2 id="section-10.8">10.8 Other Analyses</h2></div><div class=""><h2 id="section-10.9">10.9 Interim Analyses</h2></div><div class=""><h2 id="section-10.10">10.10 Multiplicity Adjustments</h2></div><div class=""><h2 id="section-10.11">10.11 Sample Size Determination</h2></div><div class="page"><h1 id="section-11">11 TRIAL OVERSIGHT AND OTHER GENERAL CONSIDERATIONS</h1></div><div class=""><h2 id="section-11.1">11.1 Regulatory and Ethical Considerations</h2></div><div class=""><h2 id="section-11.2">11.2 Trial Oversight</h2></div><div class=""><h3 id="section-11.2.1">11.2.1 Investigator Responsibilities</h3></div><div class=""><h3 id="section-11.2.2">11.2.2 Sponsor Responsibilities</h3></div><div class=""><h2 id="section-11.3">11.3 Informed Consent Process</h2></div><div class=""><h3 id="section-11.3.1">11.3.1 Informed Consent for Rescreening</h3></div><div class=""><h3 id="section-11.3.2">11.3.2 Informed Consent for Use of Remaining Samples in Exploratory Research</h3></div><div class=""><h2 id="section-11.4">11.4 Committees</h2></div><div class=""><h2 id="section-11.5">11.5 Insurance and Indemnity</h2></div><div class=""><h2 id="section-11.6">11.6 Risk Management</h2></div><div class=""><h2 id="section-11.7">11.7 Data Governance</h2></div><div class=""><h2 id="section-11.8">11.8 Source Data</h2></div><div class=""><h2 id="section-11.9">11.9 Protocol Deviations</h2></div><div class=""><h2 id="section-11.10">11.10 Early Site Closure</h2></div><div class="page"><h1 id="section-12">12 APPENDIX: SUPPORTING DETAILS</h1></div><div class=""><h2 id="section-12.1">12.1 Clinical Laboratory Tests</h2></div><div class=""><h2 id="section-12.2">12.2 Country/Region-Specific Differences</h2></div><div class=""><h2 id="section-12.3">12.3 Prior Protocol Amendment(s)</h2></div><div class="page"><h1 id="section-13">13 APPENDIX:  GLOSSARY OF TERMS AND ABBREVIATIONS</h1></div><div class="page"><h1 id="section-14">14 APPENDIX:  REFERENCES</h1></div></body></html>